dr kalinsky on the implications of destiny-breast06 for t-dxd use in her2-ultralow breast cancer
Published 9 days ago • 44 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:43
dr hamilton on implications of destiny-breast06 on the her2-low breast cancer paradigm
-
0:53
dr. kalinsky on cns involvement in her2 breast cancer
-
39:22
optimizing therapy in her2 disease with dr. kevin kalinsky
-
1:45
dr. kalinsky on neratinib and tucatinib in her2 metastatic breast cancer
-
1:42
kevin kalinsky, md, shares thoughts on the destiny-breast01 clinical trial from sabcs 2020
-
0:54
dr. kalinsky on optical imaging for her2 breast cancer
-
1:10
dr. kalinsky discusses the evolution of her2 breast cancer
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
3:15
dr curigliano on the efficacy of t-dxd in her2-low and her2-ultralow breast cancer
-
1:22
dr. hurvitz on the findings of destiny-breast01 in her2 metastatic breast cancer
-
17:53
dr. murthy on the clinical implications of tucatinib approval in her2 breast cancer
-
1:58
destiny-gastric02: t-dxd as a second-line treatment for her2-positive gastric cancer
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
1:07
dr. hamilton on the destiny-breast01 trial in her2 breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts
-
1:51
dr. kolberg on cost-effectiveness of pertuzumab in her2-positive breast cancer
-
1:09
the exciting new field of her2-low breast cancer